Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117,110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
Chalkias S, Whatley JL, Eder F, Essink B, Khetan S, Bradley P, Brosz A, McGhee N, Tomassini JE, Chen X, Zhao X, Sutherland A, Shen X, Girard B, Edwards DK, Feng J, Zhou H, Walsh S, Montefiori DC, Baden LR, Miller JM, Das R. Chalkias S, et al. Among authors: chen x. Nat Med. 2023 Sep;29(9):2325-2333. doi: 10.1038/s41591-023-02517-y. Epub 2023 Aug 31. Nat Med. 2023. PMID: 37653342 Free PMC article. Clinical Trial.
Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.
Shen X, Chalkias S, Feng J, Chen X, Zhou H, Marshall JC, Girard B, Tomassini JE, Aunins A, Das R, Montefiori DC. Shen X, et al. Among authors: chen x. N Engl J Med. 2022 Sep 29;387(13):1234-1236. doi: 10.1056/NEJMc2210648. Epub 2022 Sep 9. N Engl J Med. 2022. PMID: 36083119 Free PMC article. No abstract available.
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. Chalkias S, et al. Among authors: chen x. N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16. N Engl J Med. 2022. PMID: 36112399 Free PMC article. Clinical Trial.
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J, Chen X, Chang Y, Zhou H, Montefiori D, Edwards DK, Girard B, Pajon R, Dutko FJ, Leav B, Walsh SR, Baden LR, Miller JM, Das R. Chalkias S, et al. Among authors: chen x. Nat Med. 2022 Nov;28(11):2388-2397. doi: 10.1038/s41591-022-02031-7. Epub 2022 Oct 6. Nat Med. 2022. PMID: 36202997 Free PMC article. Clinical Trial.
Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination.
Chalkias S, Feng J, Chen X, Zhou H, Marshall JC, Girard B, Tomassini JE, Kuter BJ, Montefiori DC, Das R. Chalkias S, et al. Among authors: chen x. N Engl J Med. 2022 Dec 8;387(23):2194-2196. doi: 10.1056/NEJMc2212772. Epub 2022 Nov 23. N Engl J Med. 2022. PMID: 36416761 Free PMC article. No abstract available.
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, Kalra PA, Clark R, Dargan PI, Boffito M, Sheridan R, Moran E, Darton TC, Burns F, Saralaya D, Duncan CJA, Lillie PJ, San Francisco Ramos A, Galiza EP, Heath PT, Girard B, Parker C, Rust D, Mehta S, de Windt E, Sutherland A, Tomassini JE, Dutko FJ, Chalkias S, Deng W, Chen X, Feng J, Tracy L, Zhou H, Miller JM, Das R; Study Investigators. Lee IT, et al. Among authors: chen x. Lancet Infect Dis. 2023 Sep;23(9):1007-1019. doi: 10.1016/S1473-3099(23)00295-5. Epub 2023 Jun 19. Lancet Infect Dis. 2023. PMID: 37348519 Free article. Clinical Trial.
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Ying Chang, Sutherland A, Montefiori DC, Girard B, Edwards DK, Jing Feng, Zhou H, Baden LR, Miller JM, Das R. Chalkias S, et al. Among authors: chen x. Nat Commun. 2023 Aug 23;14(1):5125. doi: 10.1038/s41467-023-38892-w. Nat Commun. 2023. PMID: 37612300 Free PMC article.
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
Mues KE, Kirk B, Patel DA, Gelman A, Chavers LS, Talarico CA, Esposito DB, Martin D, Mansi J, Chen X, Gatto NM, Van de Velde N. Mues KE, et al. Among authors: chen x. Vaccine. 2022 Nov 8;40(47):6730-6739. doi: 10.1016/j.vaccine.2022.09.025. Epub 2022 Sep 24. Vaccine. 2022. PMID: 36163093 Free PMC article.
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, Julian R, Scott AJ, Geiger JL, Kirtane K, Robert-Tissot C, Coder B, Tasneem M, Sun J, Zheng W, Gerbereux L, Laino A, Porichis F, Pollard JR, Hou P, Sehgal V, Chen X, Morrissey M, Daghestani HN, Feldman I, Srinivasan L, Frederick JP, Brown M, Aanur P, Meehan R, Burris HA 3rd. Gainor JF, et al. Among authors: chen x. Cancer Discov. 2024 Nov 1;14(11):2209-2223. doi: 10.1158/2159-8290.CD-24-0158. Cancer Discov. 2024. PMID: 39115419 Clinical Trial.
117,110 results
You have reached the last available page of results. Please see the User Guide for more information.